Form 4: Talis Biomedical Corp: Leonard Braden Michael Reports Acquisition of Common Stock

Director Leonard Braden Michael reports acquiring 500 shares of Talis Biomedical Corp common stock at $4 per share on September 3, 2024.

Summary

• On September 3, 2024, Leonard Braden Michael, a director of Talis Biomedical Corp, acquired 500 shares of common stock at a price of $4 per share.
• Following this transaction, Mr. Michael indirectly owns 218,602 shares through BML Investment Partners, L.P.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports a transaction. The director's purchase could be seen as a slightly positive signal, but it's a small transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal.

Management Comments

• Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's purchase of company stock, which is a common occurrence.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Common Stock, Talis Biomedical Corp, TLIS, Leonard Braden Michael, BML Investment Partners